# EU-1-16-1140_public-assessment-report_20170203_20170203_darunavir-mylan-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
10 November 2016
EMA/851324/2016
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Darunavir Mylan
International non-proprietary name: darunavir
Procedure No. EMEA/H/C/004068/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
Table of contents
1. Background information on the procedure
6
6
1.1. Submission of the dossier
1.2. Steps taken for the assessment of the product
8
2. Scientific discussion
9
2.1. Introduction
9
2.2. Quality aspects
11
2.2.1. Introduction.
11
2.2.2. Active substance
11
General information
11
Manufacture, characterisation and process controls.
12
Stability.
13
2.2.3. Finished medicinal product
13
Description of the product and Pharmaceutical development
13
Manufacture of the product and process controls
15
Product specification
15
Stability of the product
16
Adventitious agents
16
2.2.4. Discussion on chemical, and pharmaceutical aspects
17
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
17
2.2.6. Recommendation(s) for future quality development
17
2.3. Non-clinical aspects
17
2.3.1. Pharmacology
17
2.3.2. Pharmacokinetics
17
2.3.3. Toxicology
18
2.3.4. Ecotoxicity/environmental risk assessment
19
2.3.5. Discussion on non-clinical aspects
19
2.3.6. Conclusion on the non-clinical aspects
19
2.4. Clinical aspects
19
2.4.1. Introduction
19
2.4.2. Pharmacokinetics
21
2.4.3. Pharmacodynamics
31
2.4.4. Post marketing experience
31
2.4.5. Discussion on clinical aspects.
31
2.4.6. Conclusions on clinical aspects
31
2.5. Risk management plan
31
2.6. PSUR submission
37
2.7. Pharmacovigilance
38
2.8. Product information
38
2.8.1. User consultation
38
Assessment report
EMA/851324/2016
Page 2/40
